Government urged to grease R&D investment wheels

Business sources say that to better enhance R&D capability in the domestic pharmaceutical industry, the current reimbursement price criteria needs to be readjusted in a manner such that new R&D fund including the intrinsic value of a product and manufacturer's endeavors should be well reflected in the process of screening drug price with guaranteed optimal profit, adding that a hospital bidding...